Astria Therapeutics, Inc. (ATXS)

NASDAQ: ATXS · IEX Real-Time Price · USD
13.60
+0.07 (0.52%)
At close: Mar 27, 2024, 4:00 PM
13.59
-0.01 (-0.07%)
After-hours: Mar 27, 2024, 7:49 PM EDT

Company Description

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States.

Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.

The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching.

The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021.

Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Astria Therapeutics, Inc.
Astria Therapeutics logo
Country United States
Founded 2008
IPO Date Jun 25, 2015
Industry Biotechnology
Sector Healthcare
Employees 59
CEO Ms. Jill C. Milne Ph.D.

Contact Details

Address:
75 State Street, Suite 1400
Boston, Massachusetts 02109
United States
Phone 617-349-1971
Website astriatx.com

Stock Details

Ticker Symbol ATXS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001454789
CUSIP Number 04635X102
ISIN Number US04635X1028
SIC Code 2834

Key Executives

Name Position
Jill C. Milne Ph.D. Co-Founder, Chief Executive Officer, President and Director
Benjamin S. Harshbarger J.D. Chief Legal Officer
Noah C. Clauser CPA Chief Financial Officer and Treasurer
Keri McGrail Senior Vice President of Human Resources
Andrea L. Matthews Chief Business Officer
Andrew A. Komjathy Chief Commercial Officer
Dr. Christopher J. Morabito M.D. Chief Medical Officer
John Ruesch Senior Vice President of Pharmaceutical Sciences and Technical Operations

Latest SEC Filings

Date Type Title
Mar 25, 2024 8-K Current Report
Mar 11, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Mar 7, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Mar 4, 2024 8-K Current Report
Mar 4, 2024 424B5 Filing
Mar 4, 2024 10-K Annual Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals